Impact of Disease-modifying Therapies on Respiratory Function in People with Neuromuscular Disorders.

Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) are neuromuscular disorders that affect muscular function. The most common causes of morbidity and mortality are respiratory complications, including restrictive lung disease, ineffective cough, and sleep-disordered breathing. The paradigm of care is changing as new disease-modifying therapies are altering disease trajectory, outcomes, expectations, as well as patient and caregiver experiences. This article provides an overview on therapeutic advances for SMA and DMD in the last 10 years, with a focus on the effects of disease-modifying therapies on respiratory function.

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure Dr R. Amin is a committee member of the American College of Chest Physicians and a pediatrics committee member of the American Thoracic Society. R. Amin holds research grants from Canadian Institutes of Health Research, Canada, Cure SMA Canada, Canada, Muscular Dystrophy Canada, Canada, VHA Home Healthcare, Canada, Boehringer-Ingelheim, Germany, Medigas, Canada, ProResp, Canada, Baxter Corporation Endowment Fund for Home Care, United States, and Ontario Ministry of Health and Long-Term Care, Canada. Dr L. Xiao is a committee member of the American College of Chest Physicians. Dr. Xiao holds research grants from Muscular Dystrophy Canada, Baxter Corporation Endowment Fund for Home Care, International Pediatric Sleep Association, United States, and the Sleep Research Society Foundation, United States.